HAEHaemonetics Corporation
What is the market doing?
No clear lean: nothing decisive, though in an uptrend.
In an uptrend, above its rising 50- and 200-day averages. Price is +56% vs its 200-day average.
Heavily shorted, settled Sep 15, 2026, about a week of normal trading to cover. Up 20% since the previous count, up from 6.7% of shares outstanding three months ago.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. Insider selling is often routine (taxes, diversification); only cluster buying is a strong tell.
How HAE is trading
Haemonetics Corporation is +135% over the past year while the S&P 500 is +18%: 116 points ahead of the market.
1-year return · S&P 500 +18%
- vs 200-day average
- +56%
vs 200-day average · a clear uptrend
- RSI (14)
- 69
RSI (14) · neutral
- Below its 52-week high
- 0.72%
Below its 52-week high
Details›
- Last close2026-10-09
- $118.73
- 1 monthS&P 500 +2.7%
- +17%
- 1 yearS&P 500 +18%
- +135%
- 5 yearsS&P 500 +88%
- +74%
- vs 50-day average$101.07
- +17%
- 52-week high
- $119.59
- 52-week low
- $47.67
- Annualised volatility
- 48%
| Year | Return |
|---|---|
| 2026 (year to date) | +48% |
| 2025 | +2.7% |
| 2024 | −8.7% |
| 2023 | +8.7% |
| 2022 | +48% |
| 2021 | −55% |
| 2020 | +3.4% |
| 2019 | +15% |
| 2018 | +72% |
| 2017 | +44% |
| Month | Years | Positive | Average |
|---|---|---|---|
| Jan | 10 | 2 of 10 | −4.1% |
| Feb | 10 | 4 of 10 | −0.07% |
| Mar | 10 | 6 of 10 | +1.1% |
| Apr | 10 | 6 of 10 | −2.1% |
| May | 10 | 6 of 10 | +4.2% |
| Jun | 10 | 6 of 10 | +4.7% |
| Jul | 11 | 8 of 11 | +3.4% |
| Aug | 11 | 8 of 11 | +4.0% |
| Sep | 11 | 5 of 11 | +0.46% |
| Oct | 11 | 5 of 11 | +1.1% |
| Nov | 10 | 7 of 10 | +11% |
| Dec | 10 | 5 of 10 | −1.5% |
End-of-day closes from IEX; the S&P 500 comparison uses SPY over the same window. Prices are a reference point, not a basis for trading decisions.